Cytokine-mediated bone destruction in rheumatoid arthritis

Journal of Immunology Research

Volumn 2014, Issue , 2014, Pages

  Jung, Seung Min ^a   Kim, Kyoung Woon ^a   Yang, Chul Woo ^a   Park, Sung Hwan ^a   Ju, Ji Hyeon ^a   Mamura, Mizuko ^b  

^a The Catholic University of Korea   (South Korea)

^b Catholic University of Korea ^*

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

B LYMPHOCYTE; BONE; BONE DESTRUCTION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; FIBROBLAST; FIBROBLAST LIKE SYNOVIOCYTE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; INFLAMMATION; INFLAMMATORY CELL; MONOCYTE; NEUTROPHIL; NONHUMAN; OSTEOCLASTOGENESIS; PATHOPHYSIOLOGY; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; T LYMPHOCYTE; BIOLOGICAL MODEL; IMMUNE SYSTEM; IMMUNOLOGY; METABOLISM; OSTEOBLAST; OSTEOCLAST; PATHOLOGY;

ARTHRITIS, RHEUMATOID; BONE AND BONES; CYTOKINES; HUMANS; IMMUNE SYSTEM; INFLAMMATION; MODELS, IMMUNOLOGICAL; OSTEOBLASTS; OSTEOCLASTS;

EID: 84923336314     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2014/263625     Document Type: Review

References (167)

1. T. Nakashima, Y. Kobayashi, S. Yamasaki et al. , "Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-κB ligand: modulation of the expression by osteotropic factors and cytokines, " Biochemical and Biophysical Research Communications, vol. 275, no. 3, pp. 768-775, 2000.
2. H. Takayanagi, S. Kim, and T. Taniguchi, "Signaling crosstalk between RANKL and interferons in osteoclast differentiation, " Arthritis Research & Therapy, vol. 4, supplement 3, pp. S227-S232, 2002.
3. S. Kotake, Y. Nanke, T. Yago, M. Kawamoto, and H. Yamanaka, "Human osteoclastogenic T cells and human osteoclastology, " Arthritis and Rheumatism, vol. 60, no. 11, pp. 3158-3163, 2009.
4. Y. Gao, F. Grassi, M. R. Ryan et al. , "IFN-γ stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation, " The Journal of Clinical Investigation, vol. 117, no. 1, pp. 122-132, 2007.
5. K. Janssens, P. ten Dijke, S. Janssens, and W. van Hul, "Transforming growth factor-β1 to the bone, " Endocrine Reviews, vol. 26, no. 6, pp. 743-774, 2005.
6. F. Yoshitake, S. Itoh, H. Narita, K. Ishihara, and S. Ebisu, "Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-κB signaling pathways, " Journal of Biological Chemistry, vol. 283, no. 17, pp. 11535-11540, 2008.
7. N. Franchimont, S. Rydziel, and E. Canalis, "Transforming growth factor-β increases interleukin-6 transcripts in osteoblasts, " Bone, vol. 26, no. 3, pp. 249-253, 2000.
8. N. J. Horwood, J. Elliott, T. J. Martin, and M. T. Gillespie, "IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro, " Journal of Immunology, vol. 166, no. 8, pp. 4915-4921, 2001.
9. W. Huang, M. H. Drissi, R. J. O'Keefe, and E. M. Schwarz, "A rapid multiparameter approach to study factors that regulate osteoclastogenesis: demonstration of the combinatorial dominant effects of TNF-α and TGF-β in RANKL-mediated osteoclastogenesis, " Calcified Tissue International, vol. 73, no. 6, pp. 584-593, 2003.
10. X. Liu, A. Kirschenbaum, S. Yao, and A. C. Levine, "Crosstalk between the interleukin-6 and prostaglandin E2 signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-κB (RANK) ligand/RANK system, " Endocrinology, vol. 146, no. 4, pp. 1991-1998, 2005.
11. A. A. Ragab, J. L. Nalepka, Y. Bi, and E. M. Greenfield, "Cytokines synergistically induce osteoclast differentiation: support by immortalized or normal calvarial cells, " American Journal of Physiology-Cell Physiology, vol. 283, no. 3, pp. C679-C687, 2002.
12. K. Kobayashi, N. Takahashi, E. Jimi et al. , "Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction, " Journal of Experimental Medicine, vol. 191, no. 2, pp. 275-285, 2000.
13. J. H. Kim, H. M. Jin, K. Kimet al. , "Themechanism of osteoclast differentiation induced by IL-1, " Journal of Immunology, vol. 183, no. 3, pp. 1862-1870, 2009.
14. O. Kudo, A. Sabokbar, A. Pocock, I. Itonaga, Y. Fujikawa, andN. A. Athanasou, "Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism, " Bone, vol. 32, no. 1, pp. 1-7, 2003.
15. J. Lam, S. Takeshita, J. E. Barker, O. Kanagawa, F. P. Ross, and S. L. Teitelbaum, "TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand, " Journal of Clinical Investigation, vol. 106, no. 12, pp. 1481-1488, 2000.
16. S. J. Moon, I. E. Ahn, H. Jung et al. , "Temporal differential effects of proinflammatory cytokines on osteoclastogenesis, " International Journal of Molecular Medicine, vol. 31, no. 4, pp. 769-777, 2013.
17. B. Osta, G. Benedetti, and P. Miossec, "Classical and paradoxical effects of TNF-alpha on bone homeostasis, " Frontiers in Immunology, vol. 5, article 48, 2014.
18. D. L. Scott andG. H. Kingsley, "Tumor necrosis factor inhibitors for rheumatoid arthritis, "The New England Journal ofMedicine, vol. 355, no. 7, pp. 704-712, 2006.
19. N. Charatcharoenwitthaya, S. Khosla, E. J. Atkinson, L. K. McCready, and B. L. Riggs, "Effect of blockade of TNF-α and interleukin-1 action on bone resorption in early postmenopausal women, " Journal of Bone and Mineral Research, vol. 22, no. 5, pp. 724-729, 2007.
20. V. K. Kawai, C. M. Stein, D. S. Perrien, and M. R. Griffin, "Effects of anti-tumor necrosis factor α agents on bone, " Current Opinion in Rheumatology, vol. 24, no. 5, pp. 576-585, 2012.
21. M. Komine, A. Kukita, T. Kukita, Y. Ogata, T. Hotokebuchi, and O. Kohashi, "Tumor necrosis factor-β cooperates with receptor activator of nuclear factor αB ligand in generation of osteoclasts in stromal cell-depleted rat bonemarrow cell culture, " Bone, vol. 28, no. 5, pp. 474-483, 2001.
22. O. Kudo, Y. Fujikawa, I. Itonaga, A. Sabokbar, T. Torisu, and N. A. Athanasou, "Proinflammatory cytokine (TNF-α/ILIα) induction of human osteoclast formation, " The Journal of Pathology, vol. 198, no. 2, pp. 220-227, 2002.
23. S. Wei, H. Kitaura, P. Zhou, F. P. Ross, and S. L. Teitelbaum, "IL-1 mediates TNF-induced osteoclastogenesis, " Journal of Clinical Investigation, vol. 115, no. 2, pp. 282-290, 2005.
24. H. Kitaura, P. Zhou, H. Kim, D. V. Novack, F. P. Ross, and S. L. Teitelbaum, "M-CSF mediates TNF-induced inflammatory osteolysis, " Journal of Clinical Investigation, vol. 115, no. 12, pp. 3418-3427, 2005.
25. S. Abbas, Y. H. Zhang, J. C. Clohisy, and Y. Abu-Amer, "Tumor necrosis factor-β inhibits pre-osteoblast differentiation through its type-1 receptor, " Cytokine, vol. 22, no. 1-2, pp. 33-41, 2003.
26. L. C. Gilbert, J. Rubin, andM. S. Nanes, "The p55 TNF receptor mediates TNF inhibition of osteoblast differentiation independently of apoptosis, " The American Journal of Physiology-Endocrinology and Metabolism, vol. 288, no. 5, pp. E1011-E1018, 2005.
27. J. A. Symons, T. L. McDowell, F. S. DiGiovine, N. C. Wood, S. J. Capper, and G. W. Duff, "Interleukin 1 in rheumatoid arthritis: potentiation of immune responses with the joint, " Lymphokine Research, vol. 8, no. 3, pp. 365-372, 1989.
28. L. A. Joosten, M. M. Helsen, T. Saxne, F. A. van De Loo, D. Heineg?ard, andW. B. vanDen Berg, "IL-1αβ blockade prevents cartilage and bone destruction in murine type II collageninduced arthritis, whereas TNF-α blockade only ameliorates joint inflammation, " Journal of Immunology, vol. 163, no. 9, pp. 5049-5055, 1999.
29. Y. Lee, N. Fujikado, H. Manaka, H. Yasuda, and Y. Iwakura, "IL-1 plays an important role in the bone metabolism under physiological conditions, " International Immunology, vol. 22, no. 10, pp. 805-816, 2010.
30. S. Simsa-Maziel, J. Zaretsky, A. Reich, Y. Koren, R. Shahar, and E. Monsonego-Ornan, "IL-1RI participates in normal growth plate development and bone modeling, " American Journal of Physiology-Endocrinology and Metabolism, vol. 305, no. 1, pp. E15-E21, 2013.
31. A. Rogers and R. Eastell, "Effects of estrogen therapy of postmenopausal women on cytokines measured in peripheral blood, " Journal of Bone andMineral Research, vol. 13, no. 10, pp. 1577-1586, 1998.
32. R. Pacifici, C. Brown, E. Puscheck et al. , "Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 12, pp. 5134-5138, 1991.
33. H. Fukushima, E. Jimi, F. Okamoto, W. Motokawa, and K. Okabe, "IL-1-induced receptor activator of NF-κB ligand in human periodontal ligament cells involves ERK-dependent PGE2 production, " Bone, vol. 36, no. 2, pp. 267-275, 2005.
34. J. Nukaga, M. Kobayashi, T. Shinki et al. , "Regulatory effects of interleukin-1β and prostaglandin E2 on expression of receptor activator of nuclear factor-κB ligand in human periodontal ligament cells, " Journal of Periodontology, vol. 75, no. 2, pp. 249-259, 2004.
35. V. Bloemen, T. Schoenmaker, T. J. de Vries, and V. Everts, "IL-1β favors osteoclastogenesis via supporting human periodontal ligament fibroblasts, " Journal of Cellular Biochemistry, vol. 112, no. 7, pp. 1890-1897, 2011.
36. N. Kim, Y. Kadono, M. Takami et al. , "Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis, " Journal of Experimental Medicine, vol. 202, no. 5, pp. 589-595, 2005.
37. K. Polzer, L. Joosten, J. Gasser et al. , "Interleukin-1 is essential for systemic inflammatory bone loss, " Annals of the Rheumatic Diseases, vol. 69, no. 1, pp. 284-290, 2010.
38. H. Okamoto, M. Yamamura, Y. Morita, S. Harada, H. Makino, and Z. Ota, "The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis, " Arthritis and Rheumatism, vol. 40, no. 6, pp. 1096-1105, 1997.
39. S. Kotake, K. Sato, K. J. Kim et al. , "Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation, " Journal of Bone and Mineral Research, vol. 11, no. 1, pp. 88-95, 1996.
40. N. C. Wood, J. A. Symons, E. Dickens, and G. W. Duff, "In situ hybridization of IL-6 in rheumatoid arthritis, " Clinical and Experimental Immunology, vol. 87, no. 2, pp. 183-189, 1992.
41. P. Garnero, E. Thompson, T. Woodworth, and J. S. Smolen, "Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone, " Arthritis and Rheumatism, vol. 62, no. 1, pp. 33-43, 2010.
42. M. A. Karsdal, G. Schett, P. Emery et al. , "IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to antitumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522), " Seminars in Arthritis and Rheumatism, vol. 42, no. 2, pp. 131-139, 2012.
43. L. A. Ehrlich and G. D. Roodman, "The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma, " Immunological Reviews, vol. 208, pp. 252-266, 2005.
44. P. Palmqvist, E. Persson, H. H. Conaway, and U. H. Lerner, "IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-κB ligand, osteoprotegerin, and receptor activator ofNF-κB in mouse calvariae, "The Journal of Immunology, vol. 169, no. 6, pp. 3353-3362, 2002.
45. C. A. O'Brien, S. C. Lin, T. Bellido, and S. C. Manolagas, "Expression levels of gp130 in bon e marrow stromal cells determine the magnitude of osteoclastogenic signals generated by IL-6-type cytokines, " Journal of Cellular Biochemistry, vol. 79, no. 4, pp. 532-541, 2000.
46. F. de Benedetti, N. Rucci, A. Del Fattore et al. , "Impaired skeletal development in interleukin-6-transgenic mice: amodel for the impact of chronic inflammation on the growing skeletal system, " Arthritis and Rheumatism, vol. 54, no. 11, pp. 3551-3563, 2006.
47. H. Kitamura, H. Kawata, F. Takahashi, Y. Higuchi, T. Furuichi, and H. Ohkawa, "Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice: a cellular relationship among hematopoietic cells, osteoblasts, and osteoclasts mediated by stromal cells in bone marrow, " The American Journal of Pathology, vol. 147, no. 6, pp. 1682-1692, 1995.
48. V. Poli, R. Balena, E. Fattori et al. , "Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion, " EMBO Journal, vol. 13, no. 5, pp. 1189-1196, 1994.
49. P. K. K. Wong, J. M. W. Quinn, N. A. Sims, A. van Nieuwenhuijze, I. K. Campbell, and I. P. Wicks, "Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigeninduced arthritis and drives inflammation-induced osteoclastogenesis, " Arthritis and Rheumatism, vol. 54, no. 1, pp. 158-168, 2006.
50. P. Miossec, T. Korn, andV. K. Kuchroo, "Interleukin-17 and type 17 helper T cells, " New England Journal ofMedicine, vol. 361, no. 9, pp. 848-898, 2009.
51. Z. Yao, S. L. Painter, W. C. Fanslow et al. , "Human IL-17: a novel cytokine derived from T cells, " Journal of Immunology, vol. 155, no. 12, pp. 5483-5486, 1995.
52. E. Lubberts, M. Koenders, andW. B. van den Berg, "The role of T cell interleukin-17 in conducting destructive arthritis: lessons from animal models, " Arthritis Research and Therapy, vol. 7, no. 1, pp. 29-37, 2005.
53. I. E. Adamopoulos, C. Chao, R. Geissler et al. , "Interleukin-17A upregulates receptor activator of NF-κB on osteoclast precursors, " Arthritis Research and Therapy, vol. 12, article R29, 2010.
54. C. C. Chao, S. J. Chen, I. E. Adamopoulos et al. , "Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis, " Autoimmunity, vol. 44, no. 3, pp. 243-252, 2011.
55. E. Lubberts, M. I. Koenders, B. Oppers-Walgreen et al. , "Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion, " Arthritis and Rheumatism, vol. 50, no. 2, pp. 650-659, 2004.
56. T. Yago, Y. Nanke, M. Kawamoto et al. , "IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats, " Arthritis Research andTherapy, vol. 9, no. 5, article no. R96, 2007.
57. J. M. W. Quinn, N. A. Sims, H. Saleh et al. , "IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bonemass in mice, " Journal of Immunology, vol. 181, no. 8, pp. 5720-5729, 2008.
58. N. Bottini and G. S. Firestein, "Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors, " Nature Reviews Rheumatology, vol. 9, no. 1, pp. 24-33, 2013.
59. T. C. Tolboom, E. Pieterman, W. H. van der Laan et al. , "Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10, " Annals of the Rheumatic Diseases, vol. 61, no. 11, pp. 975-980, 2002.
60. T. Pap, I. Meinecke, U. Müller-Ladner, and S. Gay, "Are fibroblasts involved in joint destruction?" Annals of the Rheumatic Diseases, vol. 64, no. 4, pp. iv52-iv54, 2005.
61. H. Takayanagi, H. Oda, S. Yamamoto et al. , "A newmechanism of bone destruction in rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis, " Biochemical and Biophysical Research Communications, vol. 240, no. 2, pp. 279-286, 1997.
62. E. M. Gravallese, Y. Harada, J. Wang, A. H. Gorn, T. S. Thornhill, and S. R. Goldring, "Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis, " The American Journal of Pathology, vol. 152, no. 4, pp. 943-951, 1998.
63. E. D. Harris Jr. , "Rheumatoid arthritis. Pathophysiology and implications for therapy, "The New England Journal ofMedicine, vol. 322, no. 18, pp. 1277-1289, 1990.
64. K. W. Kim, M. L. Cho, S. H. Lee et al. , "Human rheumatoid synovial fibroblasts promote osteoclastogenic activity by activating RANKL via TLR-2 and TLR-4 activation, " Immunology Letters, vol. 110, no. 1, pp. 54-64, 2007.
65. X. Li, K. Kim, M. Cho et al. , "IL-23 induces receptor activator of NF-κB ligand expression in fibroblast-like synoviocytes via STAT3 and NF-κB signal pathways, " Immunology Letters, vol. 127, no. 2, pp. 100-107, 2010.
66. K. W. Kim, H. R. Kim, J. Y. Park et al. , "Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts, " Arthritis and Rheumatism, vol. 64, no. 4, pp. 1015-1023, 2012.
67. H. R. Kim, K. W. Kim, B. M. Kim, H. G. Jung, M. L. Cho, and S. H. Lee, "Reciprocal activation of CD4+ T cells and synovial fibroblasts by stromal cell-derived factor 1 promotes RANKL expression and osteoclastogenesis in rheumatoid arthritis, " Arthritis and Rheumatism, vol. 66, no. 3, pp. 538-548, 2014.
68. F. L. Liu, C. H. Chen, S. J. Chu et al. , "Interleukin (IL)-23 p19 expression induced by IL-1β in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-κB and AP-1 dependent pathway, " Rheumatology, vol. 46, no. 8, pp. 1266-1273, 2007.
69. S. Y. Hwang, J. Y. Kim, K. W. Kim et al. , "IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-κB-and PI3-kinase/Akt-dependent pathways, " Arthritis Research & Therapy, vol. 6, no. 2, pp. R120-128, 2004.
70. C. Shi and E. G. Pamer, "Monocyte recruitment during infection and inflammation, " Nature Reviews Immunology, vol. 11, no. 11, pp. 762-774, 2011.
71. I. B. McInnes and G. Schett, "The pathogenesis of rheumatoid arthritis, "The New England Journal ofMedicine, vol. 365, no. 23, pp. 2205-2219, 2011.
72. J. Li, H. Hsu, and J. D. Mountz, "Managing macrophages in rheumatoid arthritis by reform or removal, " Current Rheumatology Reports, vol. 14, no. 5, pp. 445-454, 2012.
73. C. Cirrincione, N. Pimpinelli, L. Orlando, and P. Romagnoli, "Lamina propria dendritic cells express activation markers and contact lymphocytes in chronic periodontitis, " Journal of Periodontology, vol. 73, no. 1, pp. 45-52, 2002.
74. J. Highton, A. Kean, P. A. Hessian, J. Thomson, J. Rietveld, and D. N. J. Hart, "Cells expressing dendritic cell markers are present in the rheumatoid nodule, "The Journal of Rheumatology, vol. 27, no. 2, pp. 339-346, 2000.
75. R. Thomas, K. P. A. MacDonald, A. R. Pettit, L. L. Cavanagh, J. Padmanabha, and S. Zehntner, "Dendritic cells and the pathogenesis of rheumatoid arthritis, " Journal of Leukocyte Biology, vol. 66, no. 2, pp. 286-292, 1999.
76. G. Page, S. Lebecque, and P. Miossec, "Anatomic localization of immature and mature dendritic cells in an ectopic lymphoid organ: correlation with selective chemokine expression in rheumatoid synovium, " Journal of Immunology, vol. 168, no. 10, pp. 5333-5341, 2002.
77. G. Page and P. Miossec, "RANK and RANKL expression as markers of dendritic cell-T cell interactions in paired samples of rheumatoid synovium and lymph nodes, " Arthritis and Rheumatism, vol. 52, no. 8, pp. 2307-2312, 2005.
78. C. W. Cutler and R. Jotwani, "Dendritic cells at the oralmucosal interface, " Journal of Dental Research, vol. 85, no. 8, pp. 678-689, 2006.
79. M. Tucci, S. Stucci, S. Strippoli, F. Dammacco, and F. Silvestris, "Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression?" Oncologist, vol. 16, no. 7, pp. 1040-1048, 2011.
80. K. M. Dhodapkar, S. Barbuto, P. Matthews et al. , "Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma, " Blood, vol. 112, no. 7, pp. 2878-2885, 2008.
81. A. Rivollier, M. Mazzorana, J. Tebib et al. , "Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment, " Blood, vol. 104, no. 13, pp. 4029-4037, 2004.
82. M. Alnaeeli, J. M. Penninger, and Y. A. Teng, "Immune interactions with CD4+ T cells promote the development of functional osteoclasts from murine CD11c+ dendritic cells, " Journal of Immunology, vol. 177, no. 5, pp. 3314-3326, 2006.
83. A. Kukreja, S. Radfar, B. Sun, K. Insogna, andM. V. Dhodapkar, "Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease, " Blood, vol. 114, no. 16, pp. 3413-3421, 2009.
84. V. John, J. M. Hock, L. L. Short, A. L. Glasebrook, and R. J. S. Galvin, "A role for CD8+ T lymphocytes in osteoclast differentiation in vitro, " Endocrinology, vol. 137, no. 6, pp. 2457-2463, 1996.
85. Y. Li, G. Toraldo, A. Li et al. , "B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo, " Blood, vol. 109, no. 9, pp. 3839-3848, 2007.
86. T. R. Mosmann, H. Cherwinski, andM. W. Bond, "Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins, " Journal of Immunology, vol. 136, no. 7, pp. 2348-2357, 1986.
87. A. K. Abbas, K. M. Murphy, and A. Sher, "Functional diversity of helper T lymphocytes, " Nature, vol. 383, no. 6603, pp. 787-793, 1996.
88. T. R. Mosmann and R. L. Coffman, "TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties, " Annual Review of Immunology, vol. 7, pp. 145-173, 1989.
89. K. Sato, A. Suematsu, K. Okamoto et al. , "Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction, " Journal of Experimental Medicine, vol. 203, no. 12, pp. 2673-2682, 2006.
90. T. Kawai, T. Matsuyama, Y. Hosokawa et al. , "B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease, " The American Journal of Pathology, vol. 169, no. 3, pp. 987-998, 2006.
91. S. Kotake, Y. Nanke, M. Mogi et al. , "IFN-γ-producing human T cells directly induce osteoclastogenesis fromhuman monocytes via the expression ofRANKL, " European Journal of Immunology, vol. 35, no. 11, pp. 3353-3363, 2005.
92. E. Volpe, N. Servant, R. Zollinger et al. , "A critical function for transforming growth factor-β, interleukin 23 and proinflammatory cytokines in driving and modulating human TH-17 responses, " Nature Immunology, vol. 9, no. 6, pp. 650-657, 2008.
93. J. P. van Hamburg, P. S. Asmawidjaja, N. Davelaar et al. , "Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production, " Arthritis and Rheumatism, vol. 63, no. 1, pp. 73-83, 2011.
94. K. Noonan, L. Marchionni, J. Anderson, D. Pardoll, G. D. Roodman, and I. Borrello, "Anovel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma, " Blood, vol. 116, no. 18, pp. 3554-3563, 2010.
95. M. S. Maddur, P. Miossec, S. V. Kaveri, and J. Bayry, "Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies, " The American Journal of Pathology, vol. 181, no. 1, pp. 8-18, 2012.
96. T. Matsumoto and M. Abe, "Bone destruction in multiple myeloma, " Annals of the New York Academy of Sciences, vol. 1068, no. 1, pp. 319-326, 2006.
97. J. C. W. Edwards and G. Cambridge, "Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes, " Rheumatology, vol. 40, no. 2, pp. 205-211, 2001.
98. J. C. W. Edwards, L. Szczepański, J. Szechiński et al. , "Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis, "TheNew England Journal ofMedicine, vol. 350, no. 25, pp. 2572-2581, 2004.
99. B. Nakken, L. A. Munthe, Y. T. Konttinenet al. , "B-cells andtheir targeting in rheumatoid arthritis-current concepts and future perspectives, " Autoimmunity Reviews, vol. 11, no. 1, pp. 28-34, 2011.
100. R. Cascão, H. S. Rosário, M. M. Souto-Carneiro, and J. E. Fonseca, "Neutrophils in rheumatoid arthritis: more than simple final effectors, " Autoimmunity Reviews, vol. 9, no. 8, pp. 531-535, 2010.
101. A. Kantarci, K. Oyaizu, and T. E. van Dyke, "Neutrophilmediated tissue injury in periodontal disease pathogenesis: findings from localized aggressive periodontitis, " Journal of Periodontology, vol. 74, no. 1, pp. 66-75, 2003.
102. H. Hasturk, A. Kantarci, T. Ohira et al. , "RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis, " The FASEB Journal, vol. 20, no. 2, pp. 401-403, 2006.
103. B. T. Wipke and P. M. Allen, "Essential role of neutrophils in the initiation and progression of amurine model of rheumatoid arthritis, " Journal of Immunology, vol. 167, no. 3, pp. 1601-1608, 2001.
104. P. E. Poubelle, A. Chakravarti, M. J. Fernandes, K. Doiron, and A. Marceau, "Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patientswith rheumatoid arthritis and by healthy human blood neutrophils, " Arthritis Research and Therapy, vol. 9, no. 2, article R25, 2007.
105. A. Chakravarti, M. Raquil, P. Tessier, andP. E. Poubelle, "Surface RANKL of Toll-like receptor 4-stimulated human neutrophils activates osteoclastic bone resorption, " Blood, vol. 114, no. 8, pp. 1633-1644, 2009.
106. N. C. Walsh, K. A. Alexander, C. A. Manning et al. , "Activated human T cells express alternative mRNA transcripts encoding a secreted formof RANKL, " Genes and Immunity, vol. 14, no. 5, pp. 336-345, 2013.
107. F. Kanamaru, H. Iwai, T. Ikeda, A. Nakajima, I. Ishikawa, and M. Azuma, "Expression of membrane-bound and soluble receptor activator of NF-κB ligand (RANKL) in human T cells, " Immunology Letters, vol. 94, no. 3, pp. 239-246, 2004.
108. G. Brunetti, M. F. Faienza, L. Piacente et al. , "High dickkopf-1 levels in sera and leukocytes from children with 21-hydroxylase deficiency on chronic glucocorticoid treatment, " The American Journal of Physiology: Endocrinology and Metabolism, vol. 304, no. 5, pp. E546-E554, 2013.
109. I. Allaeys, D. Rusu, S. Picard, M. Pouliot, P. Borgeat, and P. E. Poubelle, "Osteoblast retraction induced by adherent neutrophils promotes osteoclast bone resorption: implication for altered bone remodeling in chronic gout, " Laboratory Investigation, vol. 91, no. 6, pp. 905-920, 2011.
110. B. F. Boyce, E. M. Schwarz, and L. Xing, "Osteoclast precursors: Cytokine-stimulatedimmunomodulators of inflammatory bone disease, " Current Opinion in Rheumatology, vol. 18, no. 4, pp. 427-432, 2006.
111. K. Fuller, C. Murphy, B. Kirstein, S. W. Fox, and T. J. Chambers, "TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL, " Endocrinology, vol. 143, no. 3, pp. 1108-1118, 2002.
112. H. Glantschnig, J. E. Fisher, G. Wesolowski, G. A. Rodan, and A. A. Reszka, "M-CSF, TNF-α and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase, " Cell Death and Differentiation, vol. 10, no. 10, pp. 1165-1177, 2003.
113. Y. Azuma, K. Kaji, R. Katogi, S. Takeshita, and A. Kudo, "Tumor necrosis factor-β induces differentiation of and bone resorption by osteoclasts, " Journal of Biological Chemistry, vol. 275, no. 7, pp. 4858-4864, 2000.
114. A. Yarilina, K. Xu, J. Chen, and L. B. Ivashkiv, "TNF activates calcium-nuclear factor of activated T cells (NFAT)c1 signaling pathways in human macrophages, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 4, pp. 1573-1578, 2011.
115. C. S. Lader and A. M. Flanagan, "Prostaglandin E2, interleukin and tumor necrosis factor-β increase human osteoclast formation and bone resorption in vitro, " Endocrinology, vol. 139, no. 7, pp. 3157-3164, 1998.
116. D. O' Gradaigh, D. Ireland, S. Bord, and J. E. Compston, "Joint erosion in rheumatoid arthritis: Interactions between tumour necrosis factor α, interleukin 1, and receptor activator of nuclear factor αB ligand (RANKL) regulate osteoclasts, " Annals of the Rheumatic Diseases, vol. 63, no. 4, pp. 354-359, 2004.
117. H. Kitaura, K. Kimura, M. Ishida, H. Kohara, M. Yoshimatsu, and T. Takano-Yamamoto, "Immunological reaction in TNF-α-mediated osteoclast formation and bone resorption in vitro and in vivo, " Clinical and Developmental Immunology, vol. 2013, Article ID 181849, 8 pages, 2013.
118. P. Li, E. M. Schwarz, R. J. O'Keefe, L. Ma, B. F. Boyce, and L. Xing, "RANK signaling is not required for TNF-α-mediated increase in CD11bhi osteoclast precursors but is essential for mature osteoclast formation in TNF-α-mediated inflammatory arthritis, " Journal of Bone and Mineral Research, vol. 19, no. 2, pp. 207-213, 2004.
119. J. Neidel, M. Schulze, and J. Lindschau, "Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor α in the knee-joints of patients with rheumatoid arthritis, " Inflammation Research, vol. 44, no. 5, pp. 217-221, 1995.
120. T. Ma, K. Miyanishi, A. Suen et al. , "Human interleukin-1-induced murine osteoclastogenesis is dependent on RANKL, but independent of TNF-α, " Cytokine, vol. 26, no. 3, pp. 138-144, 2004.
121. S. Lee, A. E. Gardner, J. F. Kalinowski, S. L. Jastrzebski, and J. A. Lorenzo, "RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production, " Bone, vol. 38, no. 5, pp. 678-685, 2006.
122. N. Tanabe, M. Maeno, N. Suzuki et al. , "IL-1β stimulates the formation of osteoclast-like cells by increasing M-CSF and PGE2 production and decreasing OPG production by osteoblasts, " Life Sciences, vol. 77, no. 6, pp. 615-626, 2005.
123. D. Heymann andA. Rousselle, "gp130 cytokine family and bone cells, " Cytokine, vol. 12, no. 10, pp. 1455-1468, 2000.
124. X. H. Liu, A. Kirschenbaum, S. Yao, and A. C. Levine, "The role of the interleukin-6/gp130 signaling pathway in bone metabolism, " Vitamins and Hormones, vol. 74, pp. 341-355, 2006.
125. P. K. K. Wong, I. K. Campbell, P. J. Egan, M. Ernst, and I. P. Wicks, "The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover, " Arthritis and Rheumatism, vol. 48, no. 5, pp. 1177-1189, 2003.
126. K. T. Steeve, P. Marc, T. Sandrine, H. Dominique, and F. Yannick, "IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology, "CytokineandGrowthFactorReviews, vol. 15, no. 1, pp. 49-60, 2004.
127. S. Kim, M. Yamazaki, N. K. Shevde, and J. W. Pike, "Transcriptional control of receptor activator of nuclear factor-κB ligand by the protein kinase A activator forskolin and the transmembrane glycoprotein 130-activating cytokine, oncostatin M, is exerted through multiple distal enhancers, " Molecular Endocrinology, vol. 21, no. 1, pp. 197-214, 2007.
128. C. A. O'Brien, I. Gubrij, S. Lin, R. L. Saylors, and S. C. Manolagas, "STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-κB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1, 25-dihydroxyvitamin D3 or parathyroid hormone, "The Journal of Biological Chemistry, vol. 274, no. 27, pp. 19301-19308, 1999.
129. K. Yokota, K. Sato, T. Miyazaki, H. Kitaura, H. Kayama, and F. Miyoshi, "Combination of tumor necrosis factor alpha and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo, " Arthritis & Rheumatology, vol. 66, no. 1, pp. 121-129, 2014.
130. A. Wallace, T. E. Cooney, R. Englund, and J. D. Lubahn, "Effects of interleukin-6 ablation on fracture healing in mice, " Journal of Orthopaedic Research, vol. 29, no. 9, pp. 1437-1442, 2011.
131. X. Yang, B. F. Ricciardi, A. Hernandez-Soria, Y. Shi, N. Pleshko Camacho, and M. P. G. Bostrom, "Callus mineralization and maturation are delayed during fracture healing in interleukin-6 knockout mice, " Bone, vol. 41, no. 6, pp. 928-936, 2007.
132. N. Rozen, D. Lewinson, T. Bick, Z. C. Jacob, H. Stein, and M. Soudry, "Fracture repair: modulation of fracture-callus and mechanical properties by sequential application of IL-6 following PTH 1-34 or PTH 28-48, " Bone, vol. 41, no. 3, pp. 437-445, 2007.
133. L. Duplomb, M. Baud'huin, C. Charrier et al. , "Interleukin-6 inhibits receptor activator of nuclear factor αB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of serine727 phosphorylation of signal transducer and activator of transcription 3, " Endocrinology, vol. 149, no. 7, pp. 3688-3697, 2008.
134. K. Honda, "Interleukin-6 and soluble interleukin-6 receptor suppress osteoclastic differentiation by inducing PGE(2) production in chondrocytes, " Journal of Oral Science, vol. 53, no. 1, pp. 87-96, 2011.
135. M. Darowish, R. Rahman, P. Li et al. , "Reduction of particleinduced osteolysis by interleukin-6 involves anti-inflammatory effect and inhibition of early osteoclast precursor differentiation, " Bone, vol. 45, no. 4, pp. 661-668, 2009.
136. S. Kotake, N. Udagawa, N. Takahashi et al. , "IL-17 in synovial fluids frompatients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis, " Journal of Clinical Investigation, vol. 103, no. 9, pp. 1345-1352, 1999.
137. R. L. Van Bezooijen, S. E. Papapoulos, and C. W. G. M. Löwik, "Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: is there dependency on nuclear factor-κB and receptor activator of nuclear factor αB (RANK)/RANK ligand signaling?" Bone, vol. 28, no. 4, pp. 378-386, 2001.
138. H. Kelchtermans, E. Schurgers, L. Geboes et al. , "Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-γ and counteraction by interferon-γ, " Arthritis Research and Therapy, vol. 11, no. 4, article R122, 2009.
139. R. L. Van Bezooijen, H. C. M. Farih-Sips, S. E. Papapoulos, and C. W. G. M. Löwik, "Interleukin-17: a new bone acting cytokine in vitro, " Journal of Bone andMineral Research, vol. 14, no. 9, pp. 1513-1521, 1999.
140. T. Yago, Y. Nanke, N. Ichikawa et al. , "IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-α antibody: a novel mechanism of osteoclastogenesis by IL-17, " Journal of Cellular Biochemistry, vol. 108, no. 4, pp. 947-955, 2009.
141. A. E. Oostlander, V. Everts, T. Schoenmaker et al. , "T cellmediated increased osteoclast formation fromperipheral blood as a mechanism for crohn's disease-associated bone loss, " Journal of Cellular Biochemistry, vol. 113, no. 1, pp. 260-268, 2012.
142. E. Lubberts, L. van den Bersselaar, B. Oppers-Walgreen et al. , "IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-κB ligand/ osteoprotegerin balance1, " Journal of Immunology, vol. 170, no. 5, pp. 2655-2662, 2003.
143. C. J. Deselm, Y. Takahata, J. Warren et al. , "IL-17 mediates estrogen-deficient osteoporosis in an Act1-dependent manner, " Journal of Cellular Biochemistry, vol. 113, no. 9, pp. 2895-2902, 2012.
144. A. M. Tyagi, K. Srivastava, M. N. Mansoori, R. Trivedi, N. Chattopadhyay, and D. Singh, "Estrogen deficiency induces the differentiation of IL-17 secretingTh17 cells: a new candidate in the pathogenesis of osteoporosis, " PloS one, vol. 7, no. 9, Article ID e44552, 2012.
145. D. Balani, D. Aeberli, W. Hofstetter, and M. Seitz, "Interleukin-17A stimulates granulocyte-macrophage colony-stimulating factor release by murine osteoblasts in the presence of 1, 25-dihydroxyvitamin D 3 and inhibits murine osteoclast development in vitro, " Arthritis and Rheumatism, vol. 65, no. 2, pp. 436-446, 2013.
146. S. Kitami, H. Tanaka, T. Kawato et al. , "IL-17A suppresses the expression of bone resorption-related proteinases and osteoclast differentiation via IL-17RA or IL-17RC receptors in RAW264. 7 cells, " Biochimie, vol. 92, no. 4, pp. 398-404, 2010.
147. I. E. Adamopoulos, M. Tessmer, C. Chao et al. , "IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bonemass, " Journal of Immunology, vol. 187, no. 2, pp. 951-959, 2011.
148. H. J. Ji, M. Cho, Y. Moon et al. , "IL-23 induces receptor activator of NF-κB ligand expression on CD4+ T cells and promotes osteoclastogenesis in an autoimmune arthritis model, " Journal of Immunology, vol. 181, no. 2, pp. 1507-1518, 2008.
149. Y. Hu, H. Xiong, and B. Peng, "Expression of a cytokine, interleukin-23, in experimental periapical lesions, " International Endodontic Journal, vol. 46, no. 10, pp. 896-903, 2013.
150. L. Chen, X. Wei, B. Evans, W. Jiang, and D. Aeschlimann, "IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-κB (RANK) expression in myeloid precursor cells, " European Journal of Immunology, vol. 38, no. 10, pp. 2845-2854, 2008.
151. S. Kamiya, C. Nakamura, T. Fukawa et al. , "Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation, " Journal of Bone and Mineral Metabolism, vol. 25, no. 5, pp. 277-285, 2007.
152. N. B. Binder, A. Puchner, B. Niederreiter et al. , "Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis, " Arthritis and Rheumatism, vol. 65, no. 3, pp. 608-617, 2013.
153. K. Redlich, B. Görtz, S. Hayer et al. , "Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis, " The American Journal of Pathology, vol. 164, no. 2, pp. 543-555, 2004.
154. N. Saidenberg-Kermanac'h, A. Corrado, D. Lemeiter, M. C. Devernejoul, M. C. Boissier, and M. E. Cohen-Solal, "TNF-α antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis, " Bone, vol. 35, no. 5, pp. 1200-1207, 2004.
155. R. Kitazawa, R. B. Kimble, J. L. Vannice, V. T. Kung, and R. Pacifici, "Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice, " The Journal of Clinical Investigation, vol. 94, no. 6, pp. 2397-2406, 1994.
156. R. B. Kimble, S. Bain, and R. Pacifici, "The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice, " Journal of Bone andMineral Research, vol. 12, no. 6, pp. 935-941, 1997.
157. U. Feige, Y. L. Hu, J. Gasser, G. Campagnuolo, L. Munyakazi, and B. Bolon, "Anti-interleukin-1 and anti-tumor necrosis factor-β synergistically inhibit adjuvant arthritis in lewis rats, " Cellular and Molecular Life Sciences, vol. 57, no. 10, pp. 1457-1470, 2000.
158. D. J. Shealy, P. H. Wooley, E. Emmell et al. , "Anti-TNFalpha antibody allows healing of joint damage in polyarthritic transgenic mice, " Arthritis Research, vol. 4, no. 5, p. R7, 2002.
159. J. S. Smolen, D. Aletaha, M. Koeller, M. H. Weisman, and P. Emery, "New therapies for treatment of rheumatoid arthritis, " The Lancet, vol. 370, no. 9602, pp. 1861-1874, 2007.
160. M. Mertens and J. A. Singh, "Anakinra for rheumatoid arthritis, " Cochrane Database of Systematic Reviews, no. 1, Article ID CD005121, 2009.
161. B. Bresnihan, J. M. Alvaro-Gracia, and M. Cobby, "Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist, " Arthritis and Rheumatism, vol. 41, no. 12, pp. 2196-2204, 1998.
162. K. Tanaka, M. Hashizume, M. Mihara, H. Yoshida, M. Suzuki, and Y. Matsumoto, "Anti-interleukin-6 receptor antibody prevents systemic bone mass loss via reducing the number of osteoclast precursors in bone marrow in a collagen-induced arthritis model, " Clinical and Experimental Immunology, vol. 175, no. 2, pp. 172-180, 2014.
163. R. Axmann, C. Böhm, G. Krönke, J. Zwerina, J. Smolen, and G. Schett, "Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo, " Arthritis and Rheumatism, vol. 60, no. 9, pp. 2747-2756, 2009.
164. S. Finzel, J. Rech, S. Schmidt, K. Engelke, M. Englbrecht, and G. Schett, "Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study, " Annals of the Rheumatic Diseases, vol. 72, no. 3, pp. 396-400, 2013.
165. E. Terpos, K. Fragiadaki, M. Konsta, C. Bratengeier, A. Papatheodorou, and P. P. Sfikakis, "Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis, " Clinical and Experimental Rheumatology, vol. 29, no. 6, pp. 921-925, 2011.
166. K. Zwerina, M. Koenders, A. Hueber et al. , "Anti IL-17A therapy inhibits bone loss in TNF-α-mediated murine arthritis by modulation of the T-cell balance, " European Journal of Immunology, vol. 42, no. 2, pp. 413-423, 2012.
167. M. I. Koenders, E. Lubberts, B. Oppers-Walgreen et al. , "Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1, " The American Journal of Pathology, vol. 167, no. 1, pp. 141-149, 2005.